KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks July 28, 2025
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey March 19, 2024
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 12, 2024
KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study February 23, 2024
